Novo Nordisk A/S (NYSE:NVO) Cut to Hold at Kepler Capital Markets

Kepler Capital Markets downgraded shares of Novo Nordisk A/S (NYSE:NVO) from a buy rating to a hold rating in a research report report published on Tuesday, MarketBeat Ratings reports.

A number of other analysts have also recently weighed in on the company. TD Cowen restated a “buy” rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 3rd. Deutsche Bank Aktiengesellschaft lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday. Zacks Research downgraded Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a report on Monday, February 9th. Weiss Ratings raised shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, February 5th. Finally, CICC Research started coverage on shares of Novo Nordisk A/S in a research report on Friday, January 9th. They set an “outperform” rating and a $73.50 price objective for the company. Six research analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $56.07.

Novo Nordisk A/S Trading Down 1.4%

NYSE NVO opened at $37.62 on Tuesday. Novo Nordisk A/S has a 52 week low of $37.31 and a 52 week high of $91.90. The firm has a 50 day moving average of $52.96 and a two-hundred day moving average of $52.93. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61. The stock has a market capitalization of $167.97 billion, a PE ratio of 10.84 and a beta of 0.67.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. The business had revenue of $12.43 billion for the quarter, compared to analyst estimates of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. As a group, research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The company also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be paid a $1.2751 dividend. The ex-dividend date is Monday, March 30th. This represents a yield of 541.0%. Novo Nordisk A/S’s payout ratio is currently 23.63%.

Hedge Funds Weigh In On Novo Nordisk A/S

A number of institutional investors have recently modified their holdings of the business. True Wealth Design LLC boosted its stake in Novo Nordisk A/S by 209.8% during the 3rd quarter. True Wealth Design LLC now owns 443 shares of the company’s stock worth $25,000 after purchasing an additional 300 shares during the period. Guerra Advisors Inc purchased a new stake in shares of Novo Nordisk A/S in the third quarter valued at about $25,000. Godfrey Financial Associates Inc. purchased a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at about $25,000. WealthCollab LLC boosted its stake in shares of Novo Nordisk A/S by 93.5% during the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after buying an additional 260 shares during the period. Finally, American National Bank & Trust purchased a new position in shares of Novo Nordisk A/S during the fourth quarter worth about $28,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Positive Phase‑2 China results for a triple‑agonist (UBT251) that produced ~20% body‑weight loss, bolstering Novo’s obesity pipeline and collaboration footprint in Greater China. Novo Nordisk’s China Obesity Drug Cuts Nearly One-Fifth Of Body Weight
• Positive Sentiment: Novo signed a strategic deal with Vivtex to develop next‑generation oral obesity/diabetes medicines (deal valued up to ~$2.1bn), which could extend market reach beyond injectables if the oral delivery works at scale. Novo Nordisk partners with Vivtex in up to $2.1 billion deal for oral obesity drugs
• Neutral Sentiment: Short interest fell meaningfully in February (roughly a 15% drop), reducing one source of selling pressure and lowering the days‑to‑cover — a technical datapoint worth monitoring for volatility changes.
• Negative Sentiment: Multiple analyst downgrades and coverage cuts have pressured the stock, with recent notes and headlines pointing to reduced ratings and target cuts amid pipeline and competitive concerns. Novo Nordisk A/S (NYSE:NVO) Stock Rating Lowered by Kepler Capital Markets
• Negative Sentiment: Shareholder litigation inquiries and class‑action investigations have been announced (Pomerantz, Schall Law Firm), creating legal overhang and potential costs/distraction for management. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S – NVO NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm
• Negative Sentiment: Pricing pressure and a reported halving of Wegovy prices have heightened margin and competitive concerns, feeding the narrative of a structural challenge in the obesity franchise. Novo Nordisk Cuts Wegovy Prices in Half While Its Stock Sits Near a 52-Week Low

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.